Lipigon Pharmaceuticals AB

LPGO

SE0015382072

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 11:17:01 2024-04-23 am EDT			5-day change	1st Jan Change
0.3795 ^SEK	+15.00%		+27.99%	-11.95%

Feb. 22	Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Feb. 07	Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study	MT

Lipigon Pharmaceuticals AB has completed an IPO in the amount of SEK 50.007395 million.

March 01, 2021 at 12:00 am EST

Lipigon Pharmaceuticals AB (publ) has completed an IPO in the amount of SEK 50.007395 million.

Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 4,464,946
PriceRange: SEK 11.2

Transaction Features: Rights Offering

Latest news about Lipigon Pharmaceuticals AB

Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study	Feb. 07	MT
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense	Feb. 07	CI
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials	Dec. 12	CI
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®	Nov. 23	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Lipigon Applies for Clinical Trial Phase II for Lipisense	Nov. 13	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial	23-07-12	CI
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China	23-06-27	MT
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd	23-06-27	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense	23-01-19	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Lipigon Pharmaceuticals AB Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense	22-10-05	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Lipigon Pharmaceuticals AB Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe	22-06-09	CI
Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense	22-05-31	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-03	CI
Lipigon Receives CTA Approval for Lipid-Lowering Candidate Lipisense	22-04-27	CI
Lipigon Pharmaceuticals AB and HitGen Inc. Announce Achievement of an Important Milestone in Dyslipidemia Project	22-03-21	CI
Lipigon Pharmaceuticals AB Submits CTA for Lipid-Lowering Drug Candidate Lipisense	22-03-10	CI
Lipigon Pharmaceuticals AB Confirms Patent Application for Drug Candidate Lipisense in US	22-03-01	CI

Chart Lipigon Pharmaceuticals AB

Duration

Period

More charts

Company Profile

Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIPIGON PHARMACEUTICALS AB	-11.95%	3.82M
ELI LILLY AND COMPANY	+27.33%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.61%	359B
MERCK & CO., INC.	+16.83%	322B
ABBVIE INC.	+9.59%	297B
ASTRAZENECA PLC	+6.09%	215B
NOVARTIS AG	+4.82%	210B
ROCHE HOLDING AG	-6.01%	200B
PFIZER, INC.	-8.18%	149B

Other Pharmaceuticals